Advances in development of phosphatidylinositol 3-kinase inhibitors

Current Medicinal Chemistry

Volumn 16, Issue 22, 2009, Pages 2839-2854

  Kong, Dexin ^a   Yamori, Takao ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

Biomarker; Cancer; Phosphatidylinositol 3 kinase inhibitor; Structure activity relationship

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; BGT 226; DOCETAXEL; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GDC 0941; GEMCITABINE; GSK 615; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P110; PROTEIN TYROSINE KINASE; PX 866; PX 886; SF 1126; TG 100115; TG 100115TAGE; UNCLASSIFIED DRUG; WORTMANNIN; XL 147; XL 765;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ASTHMA; AUTOIMMUNE DISEASE; BRAIN TUMOR; BREAST CANCER; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; GLIOBLASTOMA; GLOMERULONEPHRITIS; HEART INFARCTION; HUMAN; IC 50; ISCHEMIC HEART DISEASE; KAPOSI SARCOMA; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349391226     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788803222     Document Type: Review

References (120)

1. Toker, A.; Cantley, L.C. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature, 1997, 387, 673-6.
2. Vanhaesebroeck, B.; Leevers, S.J.; Panayotou, G.; Waterfield, M.D. Phosphoinositide 3-kinases: A conserved family of signal transducers. Trends Biochem. Sci., 1997, 22, 267-72.
3. Whitman, M.; Downes, C.P.; Keeler, M.; Keller, T.; Cantley, L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature, 1988, 332, 644-6.
4. Franke, T.F.; Kaplan, D.R.; Cantley, L.C. PI3K: Downstream AKTion blocks apoptosis. Cell, 1997, 88, 435-7.
5. Shepherd, P.R.; Withers, D.J.; Siddle, K. Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling. Biochem. J., 1998, 333 (Pt 3), 471-90.
6. Ihle, N.T.; Powis, G. Take your PIK: Phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol. Cancer Ther., 2009, 8, 1-9.
7. Wymann, M.P.; Pirola, L. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta, 1998, 1436, 127-50.
8. Vanhaesebroeck, B.; Leevers, S.J.; Ahmadi, K.; Timms, J.; Katso, R.; Driscoll, P.C.; Woscholski, R.; Parker, P.J.; Waterfield, M.D. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem., 2001, 70, 535-602.
9. Carracedo, A.; Pandolfi, P.P. The PTEN-PI3K pathway: Of feedbacks and cross-talks. Oncogene, 2008, 27, 5527-41.
10. Murray, J.T.; Panaretou, C.; Stenmark, H.; Miaczynska, M.; Backer, J.M. Role of Rab5 in the recruitment of hVps34/p150 to the early endosome. Traffic, 2002, 3, 416-27.
11. Christoforidis, S.; Miaczynska, M.; Ashman, K.; Wilm, M.; Zhao, L.; Yip, S.C.; Waterfield, M.D.; Backer, J.M.; Zerial, M. Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat. Cell. Biol., 1999, 1, 249-52.
12. Backer, J.M. The regulation and function of Class III PI3Ks: Novel roles for Vps34. Biochem. J., 2008, 410, 1-17.
13. D'Angelo, G.; Vicinanza, M.; Di Campli, A.; De Matteis, M.A. The multiple roles of PtdIns(4)P - not just the precursor of PtdIns(4,5)P2. J. Cell Sci., 2008, 121, 1955-63.
14. Balla, A.; Balla, T. Phosphatidylinositol 4-kinases: Old enzymes with emerging functions. Trends Cell Biol., 2006, 16, 351-61.
15. Marone, R.; Cmiljanovic, V.; Giese, B.; Wymann, M.P. Targeting phosphoinositide 3-kinase: Moving towards therapy. Biochim. Biophys. Acta, 2008, 1784, 159-85.
16. Rodriguez-Viciana, P.; Warne, P.H.; Dhand, R.; Vanhaesebroeck, B.; Gout, I.; Fry, M.J.; Waterfield, M.D.; Downward, J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature, 1994, 370, 527-32.
17. Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov., 2005, 4, 988-1004.
18. Vanhaesebroeck, B.; Ali, K.; Bilancio, A.; Geering, B.; Foukas, L.C. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem. Sci., 2005, 30, 194-204.
19. Rommel, C.; Camps, M.; Ji, H. PI3K delta and PI3K gamma: Partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol., 2007, 7, 191-201.
20. Chantry, D.; Vojtek, A.; Kashishian, A.; Holtzman, D.A.; Wood, C.; Gray, P.W.; Cooper, J.A.; Hoekstra, M.F. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem., 1997, 272, 19236-41.
21. Vanhaesebroeck, B.; Welham, M.J.; Kotani, K.; Stein, R.; Warne, P.H.; Zvelebil, M.J.; Higashi, K.; Volinia, S.; Downward, J.; Waterfield, M.D. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 4330-5.
22. Bi, L.; Okabe, I.; Bernard, D.J.; Nussbaum, R.L. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm. Genome, 2002, 13, 169-72.
23. Bi, L.; Okabe, I.; Bernard, D.J.; Wynshaw-Boris, A.; Nussbaum, R.L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J. Biol. Chem., 1999, 274, 10963-8.
24. Jia, S.; Liu, Z.; Zhang, S.; Liu, P.; Zhang, L.; Lee, S.H.; Zhang, J.; Signoretti, S.; Loda, M.; Roberts, T.M.; Zhao, J.J. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature, 2008, 454, 776-9.
25. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S.M.; Riggins, G.J.; Willson, J.K.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304, 554.
26. Levine, D.A.; Bogomolniy, F.; Yee, C.J.; Lash, A.; Barakat, R.R.; Borgen, P.I.; Boyd, J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res., 2005, 11, 2875-8.
27. Whyte, D.B.; Holbeck, S.L. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem. Biophys. Res. Commun., 2006, 340, 469-75.
28. Shayesteh, L.; Lu, Y.; Kuo, W.L.; Baldocchi, R.; Godfrey, T.; Collins, C.; Pinkel, D.; Powell, B.; Mills, G.B.; Gray, J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet., 1999, 21, 99-102.
29. Campbell, I.G.; Russell, S.E.; Choong, D.Y.; Montgomery, K.G.; Ciavarella, M.L.; Hooi, C.S.; Cristiano, B.E.; Pearson, R.B.; Phillips, W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res., 2004, 64, 7678-81.
30. Knight, Z.A.; Gonzalez, B.; Feldman, M.E.; Zunder, E.R.; Goldenberg, D.D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W.A.; Williams, R.L.; Shokat, K.M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell, 2006, 125, 733-47.
31. Jackson, S.P.; Schoenwaelder, S.M.; Goncalves, I.; Nesbitt, W.S.; Yap, C.L.; Wright, C.E.; Kenche, V.; Anderson, K.E.; Dopheide, S.M.; Yuan, Y.; Sturgeon, S.A.; Prabaharan, H.; Thompson, P.E.; Smith, G.D.; Shepherd, P.R.; Daniele, N.; Kulkarni, S.; Abbott, B.; Saylik, D.; Jones, C.; Lu, L.; Giuliano, S.; Hughan, S.C.; Angus, J.A.; Robertson, A.D.; Salem, H.H. PI 3-kinase p110beta: A new target for antithrombotic therapy. Nat. Med., 2005, 11, 507-14.
32. Wee, S.; Wiederschain, D.; Maira, S.M.; Loo, A.; Miller, C.; de-Beaumont, R.; Stegmeier, F.; Yao, Y.M.; Lengauer, C. PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 13057-62.
33. Okkenhaug, K.; Bilancio, A.; Farjot, G.; Priddle, H.; Sancho, S.; Peskett, E.; Pearce, W.; Meek, S.E.; Salpekar, A.; Waterfield, M.D.; Smith, A.J.; Vanhaesebroeck, B. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science, 2002, 297, 1031-4.
34. Del Prete, A.; Vermi, W.; Dander, E.; Otero, K.; Barberis, L.; Luini, W.; Bernasconi, S.; Sironi, M.; Santoro, A.; Garlanda, C.; Facchetti, F.; Wymann, M.P.; Vecchi, A.; Hirsch, E.; Mantovani, A.; Sozzani, S. Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J., 2004, 23, 3505-15.
35. Hirsch, E.; Katanaev, V.L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozzani, S.; Mantovani, A.; Altruda, F.; Wymann, M.P. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science, 2000, 287, 1049-53.
36. Puri, K.D.; Doggett, T.A.; Douangpanya, J.; Hou, Y.; Tino, W.T.; Wilson, T.; Graf, T.; Clayton, E.; Turner, M.; Hayflick, J.S.; Diacovo, T.G. Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood, 2004, 103, 3448-56.
37. Li, Z.; Jiang, H.; Xie, W.; Zhang, Z.; Smrcka, A.V.; Wu, D. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science, 2000, 287, 1046-9.
38. Sasaki, T.; Irie-Sasaki, J.; Jones, R.G.; Oliveira-dos-Santos, A.J.; Stanford, W.L.; Bolon, B.; Wakeham, A.; Itie, A.; Bouchard, D.; Kozieradzki, I.; Joza, N.; Mak, T.W.; Ohashi, P.S.; Suzuki, A.; Penninger, J.M. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science, 2000, 287, 1040-6.
39. Barber, D.F.; Bartolome, A.; Hernandez, C.; Flores, J.M.; Redondo, C.; Fernandez-Arias, C.; Camps, M.; Ruckle, T.; Schwarz, M.K.; Rodriguez, S.; Martinez, A.C.; Balomenos, D.; Rommel, C.; Carrera, A.C. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med., 2005, 11, 933-5.
40. Camps, M.; Ruckle, T.; Ji, H.; Ardissone, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Francon, B.; Martin, T.; Gretener, D.; Perrin, D.; Leroy, D.; Vitte, P.A.; Hirsch, E.; Wymann, M.P.; Cirillo, R.; Schwarz, M.K.; Rommel, C. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med., 2005, 11, 936-43.
41. Sadhu, C.; Masinovsky, B.; Dick, K.; Sowell, C.G.; Staunton, D.E. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol., 2003, 170, 2647-54.
42. Yuan, T.L.; Cantley, L.C. PI3K pathway alterations in cancer: Variations on a theme. Oncogene, 2008, 27, 5497-510.
43. LoPiccolo, J.; Blumenthal, G.M.; Bernstein, W.B.; Dennis, P.A. Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist. Updat., 2008, 11, 32-50.
44. Wendel, H.G.; De Stanchina, E.; Fridman, J.S.; Malina, A.; Ray, S.; Kogan, S.; Cordon-Cardo, C.; Pelletier, J.; Lowe, S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 2004, 428, 332-7.
45. Giles, F.J.; Albitar, M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr. Mol. Med., 2005, 5, 653-61.
46. Skinner, H.D.; Zheng, J.Z.; Fang, J.; Agani, F.; Jiang, B.H. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J. Biol. Chem., 2004, 279, 45643-51.
47. Harrington, L.S.; Findlay, G.M.; Gray, A.; Tolkacheva, T.; Wigfield, S.; Rebholz, H.; Barnett, J.; Leslie, N.R.; Cheng, S.; Shepherd, P.R.; Gout, I.; Downes, C.P.; Lamb, R.F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell. Biol., 2004, 166, 213-23.
48. Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 2005, 8, 179-83.
49. Vogt, P.K.; Kang, S. Kinase inhibitors: Vice becomes virtue. Cancer Cell, 2006, 9, 327-8.
50. Sun, S.Y.; Rosenberg, L.M.; Wang, X.; Zhou, Z.; Yue, P.; Fu, H.; Khuri, F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res., 2005, 65, 7052-8.
51. Fan, Q.W.; Knight, Z.A.; Goldenberg, D.D.; Yu, W.; Mostov, K.E.; Stokoe, D.; Shokat, K.M.; Weiss, W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 2006, 9, 341-9.
52. Fan, Q.W.; Weiss, W.A. Isoform specific inhibitors of PI3 kinase in glioma. Cell Cycle, 2006, 5, 2301-5.
53. Walker, E.H.; Perisic, O.; Ried, C.; Stephens, L.; Williams, R.L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature, 1999, 402, 313-20.
54. Walker, E.H.; Pacold, M.E.; Perisic, O.; Stephens, L.; Hawkins, P.T.; Wymann, M.P.; Williams, R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell, 2000, 6, 909-19.
55. Levy, J.; Teuerstein, I.; Marbach, M.; Radian, S.; Sharoni, Y. Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin. Biochem. Biophys. Res. Commun., 1984, 123, 1227-33.
56. Srivastava, A.K. Inhibition of phosphorylase kinase, and tyrosine protein kinase activities by quercetin. Biochem. Biophys. Res. Commun., 1985, 131, 1-5.
57. Gschwendt, M.; Horn, F.; Kittstein, W.; Marks, F. Inhibition of the calcium- and phospholipid-dependent protein kinase activity from mouse brain cytosol by quercetin. Biochem. Biophys. Res. Commun., 1983, 117, 444-7.
58. Cochet, C.; Feige, J.J.; Pirollet, F.; Keramidas, M.; Chambaz, E.M. Selective inhibition of a cyclic nucleotide independent protein kinase (G type casein kinase) by quercetin and related polyphenols. Biochem. Pharmacol., 1982, 31, 1357-61.
59. Graziani, Y.; Erikson, E.; Erikson, R.L. The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo. Eur. J. Biochem., 1983, 135, 583-9.
60. Vlahos, C.J.; Matter, W.F.; Hui, K.Y.; Brown, R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl -4H-1-benzopyran-4-one (LY294002). J. Biol. Chem., 1994, 269, 5241-8.
61. Davies, S.P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 2000, 351, 95-105.
62. Kong, D.; Yaguchi, S.; Yamori, T. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol. Pharm. Bull., 2009, 32, 297-300.
63. Hu, L.; Zaloudek, C.; Mills, G.B.; Gray, J.; Jaffe, R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res., 2000, 6, 880-6.
64. Casagrande, F.; Bacqueville, D.; Pillaire, M.J.; Malecaze, F.; Manenti, S.; Breton-Douillon, M.; Darbon, J.M. G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells. FEBS Lett., 1998, 422, 385-90.
65. Jiang, B.H.; Zheng, J.Z.; Aoki, M.; Vogt, P.K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 1749-53.
66. Rosenzweig, K.E.; Youmell, M.B.; Palayoor, S.T.; Price, B.D. Radiosensitization of human tumor cells by the phosphatidylinosito13-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin. Cancer Res., 1997, 3, 1149-56
67. Su, J.D.; Mayo, L.D.; Donner, D.B.; Durden, D.L. PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment. Cancer Res., 2003, 63, 3585-92.
68. Brian, P.W.; Curtis P.J.; Hemming, H.G.; Norris, G.L.F. Wortmannin, an antibiotic produced by penicillium wortmanni. Trans. Br. Mycol. Soc., 1957, 40, 365-8.
69. Petcher, T.J.; Weber, H.; Kis, Z. Crystal structure and absolute configuration of wortmannin and of wortmannin p-bromobenzoate. J. Chem. Soc. Chem. Commun., 1972, 3, 1061-2.
70. Wiesinger, D.; Gubler, H.U.; Haefliger, W.; Hauser, D. Antiinflammatory activity of the new mould metabolite 11-desacetoxy-wortmannin and of some of its derivatives. Experientia, 1974, 30, 135-6.
71. Powis, G.; Bonjouklian, R.; Berggren, M.M.; Gallegos, A.; Abraham, R.; Ashendel, C.; Zalkow, L.; Matter, W.F.; Dodge, J.; Grindey, G.; et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res., 1994, 54, 2419-23.
72. Okada, T.; Sakuma, L.; Fukui, Y.; Hazeki, O.; Ui, M. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J. Biol. Chem., 1994, 269, 3563-7.
73. Arcaro, A.; Wymann, M.P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J., 1993, 296(Pt 2), 297-301.
74. Nakanishi, S.; Kakita, S.; Takahashi, I.; Kawahara, K.; Tsukuda, E.; Sano, T.; Yamada, K.; Yoshida, M.; Kase, H.; Matsuda, Y.; Hashimoto, Y.; Nonomura, Y. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J. Biol. Chem., 1992, 267, 2157-63
75. Liu, Y.; Shreder, K.R.; Gai, W.; Corral, S.; Ferris, D.K.; Rosenblum, J.S. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol., 2005, 12, 99-107.
76. Wymann, M.P.; Bulgarelli-Leva, G.; Zvelebil, M.J.; Pirola, L.; Vanhaesebroeck, B.; Waterfield, M.D.; Panayotou, G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol., 1996, 16, 1722-33.
77. Ihle, N.T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M.I.; Paine-Murrieta, G.; Minion, D.J.; Halter, R.J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther., 2004, 3, 763-72.
78. Sarkaria, J.N.; Tibbetts, R.S.; Busby, E.C.; Kennedy, A.P.; Hill, D.E.; Abraham, R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res., 1998, 58, 4375-82.
79. Sturgeon, S.A.; Jones, C.; Angus, J.A.; Wright, C.E. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Eur. J. Pharmacol., 2008, 587, 209-15.
80. Lee, K.S.; Lee, H.K.; Hayflick, J.S.; Lee, Y.C.; Puri, K.D. Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J., 2006, 20, 455-65.
81. Sujobert, P.; Bardet, V.; Cornillet-Lefebvre, P.; Hayflick, J.S.; Prie, N.; Verdier, F.; Vanhaesebroeck, B.; Muller, O.; Pesce, F.; Ifrah, N.; Hunault-Berger, M.; Berthou, C.; Villemagne, B.; Jourdan, E.; Audhuy, B.; Solary, E.; Witz, B.; Harousseau, J.L.; Himberlin, C.; Lamy, T.; Lioure, B.; Cahn, J.Y.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood, 2005, 106, 1063-6.
82. Billottet, C.; Grandage, V.L.; Gale, R.E.; Quattropani, A.; Rommel, C.; Vanhaesebroeck, B.; Khwaja, A. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene, 2006, 25, 6648-59.
83. Tamburini, J.; Chapuis, N.; Bardet, V.; Park, S.; Sujobert, P.; Willems, L.; Ifrah, N.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeutic inhibition of both pathways. Blood, 2008, 111, 379-82.
84. Doukas, J.; Wrasidlo, W.; Noronha, G.; Dneprovskaia, E.; Fine, R.; Weis, S.; Hood, J.; Demaria, A.; Soll, R.; Cheresh, D. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U S A, 2006, 103, 19866-71.
85. Ihle, N.T.; Paine-Murrieta, G.; Berggren, M.I.; Baker, A.; Tate, W.R.; Wipf, P.; Abraham, R.T.; Kirkpatrick, D.L.; Powis, G. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol. Cancer Ther., 2005, 4, 1349-57.
86. Ihle, N.T.; Lemos, R., Jr.; Wipf, P.; Yacoub, A.; Mitchell, C.; Siwak, D.; Mills, G.B.; Dent, P.; Kirkpatrick, D.L.; Powis, G. Mutations in the phosphatidylinositol-3-kinase pathway predict for anti-tumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res., 2009, 69, 143-50.
87. Raynaud, F.I.; Eccles, S.; Clarke, P.A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L.M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res., 2007, 67, 5840-50.
88. Fan, Q.W.; Cheng, C.K.; Nicolaides, T.P.; Hackett, C.S.; Knight, Z.A.; Shokat, K.M.; Weiss, W.A. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res., 2007, 67, 7960-5.
89. Chaisuparat, R.; Hu, J.; Jham, B.C.; Knight, Z.A.; Shokat, K.M.; Montaner, S. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res., 2008, 68, 8361-8.
90. Halatsch, M.E.; Schmidt, U.; Behnke-Mursch, J.; Unterberg, A.; Wirtz, C.R. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat. Rev., 2006, 32, 74-89.
91. Mueller, W.; Mizoguchi, M.; Silen, E.; D'Amore, K.; Nutt, C.L.; Louis, D.N. Mutations of the PIK3CA gene are rare in human glioblastoma. Acta Neuropathol., 2005, 109, 654-5.
92. Folkes, A.J.; Ahmadi, K.; Alderton, W.K.; Alix, S.; Baker, S.J.; Box, G.; Chuckowree, I.S.; Clarke, P.A.; Depledge, P.; Eccles, S.A.; Friedman, L.S.; Hayes, A.; Hancox, T.C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A.G.; Pang, J.; Patel, S.; Pergl-Wilson, G.H.; Raynaud, F.I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M.H.; Valenti, M.; Wallweber, H.J.; Wan, N.C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M.J.; Shuttleworth, S.J. The identification of 2-(1H-indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin -4-yl-thieno [3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51, 5522-32.
93. Edgar, K.A.; Wallin, J.J.; Wu, H.; Heffron, T.; Olivero, A.; Saghir, N.; Friedman, L.S.; Belvin, M. Increased role of the p110 betta isoform of PI3-kinase in PTEN deficient breast cancer cells. Proc. AACR, 2008, supplement, page 9.
94. Friedman, L.; Belvin, M.; Couter, J.L.; Lin, K.; Robillard, L.; Sampath, D.; Stern, H.; Ye, W.; Vijapurkar, U.; Plowman, G. Antiangiogenic effects of PI3K/Akt/mTOR pathway inhibitors. Eur. J. Cancer, 2008, 6, 71s.
95. Patel, S.; Sampath, D.; Belvin, M.; Brown, A.; Edgar, K.; Lensun, L.; Moore, P.; Salphati, L.; Stern, H.; Friedman, L. Preclinical evaluation of the efficacy and PK/PD biomarkers of GDC-0941, a potent class 1 PI3K inhibitor. Eur. J. Cancer, 2008, 6, 69s.
96. Sampath, D.; Belvin, M.; Guan, J.; Edgar, K.; Wallin, J.; Prior, W.W.; Oeh, J.; Kassees, R.; Berry, L.; Moore, P.; Patel, S.; Friedman, L. Combination of class I PI3K inhibitor, GDC-0941, with standard of care therapeutics results in enhanced antitumor responses in human cancer models in vitro and in vivo. Eur. J. Cancer, 2008, 6, 69s-70s.
97. Maira, S.M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther., 2008, 7, 1851-63.
98. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P.J.; Valero, V.; Guzman, M.; Botero, M.L.; Llonch, E.; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Parra, J.L.; Arribas, J.; Baselga, J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res., 2008, 68, 8022-30.
99. Schnell, C.R.; Stauffer, F.; Allegrini, P.R.; O'Reilly, T.; McSheehy, P.M.; Dartois, C.; Stumm, M.; Cozens, R.; Littlewood-Evans, A.; Garcia-Echeverria, C.; Maira, S.M. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: Implications for clinical imaging. Cancer Res., 2008, 68, 6598-607.
100. Garlich, J.R.; De, P.; Dey, N.; Su, J.D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G.B.; Kundra, V.; Shu, H.K.; Peng, Q.; Durden, D.L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res., 2008, 68, 206-15.
101. Auger, K.R.; Luo, L.; Knight, S.; Aller, G.V.; Tummino, P.J.; Copeland, R.A.; Diamond, M.; Sutton, D.; Lu, H.; Oleykowski, K.; Sudakin, V.; Dhanak, D.; Jackson, J.R. GSK1059615: A novel inhibitor of phosphoinositide 3-kinase for the treatment of cancer. Eur. J. Cancer, 2008, 6, 70s.
102. Yaguchi, S.; Fukui, Y.; Koshimizu, I.; Yoshimi, H.; Matsuno, T.; Gouda, H.; Hirono, S.; Yamazaki, K.; Yamori, T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst., 2006, 98, 545-56.
103. Kong, D.; Yamori, T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci., 2007, 98, 1638-42.
104. Kong, D.; Yamori, T. Phosphatidylinositol 3-kinase inhibitors: Promising drug candidates for cancer therapy. Cancer Sci., 2008, 99, 1734-40.
105. Dan, S.; Yoshimi, H.; Okamura, M.; Mukai, Y.; Yamori, T. Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/ G1 arrest. Biochem. Biophys. Res. Commun., 2009, 379, 104-9.
106. Kong, D.; Okamura, M.; Yoshimi, H.; Yamori, T. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. Eur. J. Cancer, 2009, 45, 857-65.
107. Patnaik, A.L.; LoRussso, P.M.; Tabernero, J.; Laird, A.D.; Aggarwal, S.K.; Papadopoulos, K.P. Biomarker development for XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a Phase I clinical trial. Mol. Cancer Ther., 2007, 6, 3516s.
108. Shapiro, G.I.E., G.; Calvo, E.; Aggarwal, S.K.; Laird, A.D. Targeting aberrant PI3K pathway signaling with XL147, a potent, selective, and orally bioavailable PI3K inhibitor. Mol. Cancer Ther., 2007, 6, 3594s.
109. Atkinson, A.J.; Colburn, W.A.; DeGruttola, V.G.; DeMets, D.L.; Downing DO, G.J.; Hoth,D.F.; Oates, J.A.; Peck, C.C.; Schooley, R.T.; Spilker, B.A.; Woodcock, J.; Zeger, S.L. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69, 89-95.
110. Yap, T.A.; Garrett, M.D.; Walton, M.I.; Raynaud, F.; de Bono, J.S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr. Opin. Pharmacol., 2008, 8, 393-412.
111. Williams, R.; Baker, A.F.; Ihle, N.T.; Winkler, A.R.; Kirkpatrick, L.; Powis, G. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemother. Pharmacol., 2006, 58, 444-50.
112. LoRusso, P., Sarker, D., Hoff, D.V., Tibes, R., Derynck, M.K., Ware, J.A., Yan, Y., Demetri, G.D., de Bono, J.S., Wagner, A.J. Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation. Eur. J. Cancer, 2008, 6, 70s.
113. Palanki, M.S.; Dneprovskaia, E.; Doukas, J.; Fine, R.M.; Hood, J.; Kang, X.; Lohse, D.; Martin, M.; Noronha, G.; Soll, R.M.; Wrasidlo, W.; Yee, S.; Zhu, H. Discovery of 3,3′-(2,4-diaminopteridine-6,7 -diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. J. Med. Chem., 2007, 50, 4279-94.
114. Pomel, V.; Klicic, J.; Covini, D.; Church, D.D.; Shaw, J.P.; Roulin, K.; Burgat-Charvillon, F.; Valognes, D.; Camps, M.; Chabert, C.; Gillieron, C.; Francon, B.; Perrin, D.; Leroy, D.; Gretener, D.; Nichols, A.; Vitte, P.A.; Carboni, S.; Rommel, C.; Schwarz, M.K.; Ruckle, T. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem., 2006, 49, 3857-71.
115. Kang, S.; Denley, A.; Vanhaesebroeck, B.; Vogt, P.K. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U S A, 2006, 103, 1289-94.
116. Markman, B.L., P.M.; Patnaik, A.; Heath, E.; Laird, A.D.; van Leeuwen, B.; Papadopoulos, K.P.; Baselga, J. A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors. Eur. J. Cancer, 2008, 6, 68s.
117. Calvo, E.E., G.; Baselga, J.; Kwak, E.; Scheffold, C.; Nguyen, L.; Shapiro, G.I. A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors. Eur. J. Cancer, 2008, 6, 69s.
118. Kim, J.; Jonasch, E.; Alexander, A.; Short, J.D.; Cai, S.; Wen, S.; Tsavachidou, D.; Tamboli, P.; Czerniak, B.A.; Do, K.A.; Wu, K.J.; Marlow, L.A.; Wood, C.G.; Copland, J.A.; Walker, C.L. Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma. Clin. Cancer Res., 2009, 15, 81-90.
119. Qian, J.; Zou, Y.; Rahman, J.S.; Lu, B.; Massion, P.P. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol. Cancer Ther., 2009, 8, 101-9.
120. Zhang, H.M.; Chen, S.R.; Pan, H.L. Effects of activation of group III metabotropic glutamate receptors on spinal synaptic transmission in a rat model of neuropathic pain. Neuroscience, 2009, 158, 875-84.